WallStreetZenWallStreetZen

NASDAQ: PCRX
Pacira Biosciences Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for PCRX

Based on 1 analyst offering 12 month price targets for Pacira Biosciences Inc

Min Forecast
$30.00+31.75%
Avg Forecast
$30.00+31.75%
Max Forecast
$30.00+31.75%

Should I buy or sell PCRX stock?

Based on 1 analyst offering ratings for Pacira Biosciences Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model agrees with analyst consensus with a "Buy" rating. Learn More

Be the first to know when Wall Street analysts revise their PCRX stock forecasts and price targets.

PCRX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-05-09

1 of 1

Forecast return on equity

Is PCRX forecast to generate an efficient return?

Company
N/A
Industry
29.34%
Market
-61.61%

Forecast return on assets

Is PCRX forecast to generate an efficient return on assets?

Company
N/A
Industry
14.08%

PCRX earnings per share forecast

What is PCRX's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$1.95
Avg 2 year Forecast
$2.24
Avg 3 year Forecast
$2.54

PCRX revenue forecast

What is PCRX's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$735.2M+4.15%
Avg 2 year Forecast
$808.9M+14.6%
Avg 3 year Forecast
$873.1M+23.69%
PCRX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

PCRX revenue growth forecast

How is PCRX forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
7.43%
Industry
4.66%
Market
11.9%
PCRX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
PCRX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

PCRX vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
PCRX$22.77$30.00+31.75%Buy
COLL$33.21$40.50+21.95%Buy
CRON$2.48N/AN/A
AMPH$23.22$31.60+36.09%Buy
DVAX$9.80$21.00+114.29%Sell
View Top Pharmaceutical Stocks

Pacira Biosciences Stock Forecast FAQ

Is Pacira Biosciences Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: PCRX) stock is to Buy PCRX stock.

Out of 1 analyst, 0 (0%) are recommending PCRX as a Strong Buy, 1 (100%) are recommending PCRX as a Buy, 0 (0%) are recommending PCRX as a Hold, 0 (0%) are recommending PCRX as a Sell, and 0 (0%) are recommending PCRX as a Strong Sell.

If you're new to stock investing, here's how to buy Pacira Biosciences stock.

What is PCRX's earnings growth forecast for 2025-2027?

(NASDAQ: PCRX) Pacira Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 23.19%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 16%.

Pacira Biosciences's earnings in 2025 is -$127,460,000.On average, 4 Wall Street analysts forecast PCRX's earnings for 2025 to be $87,731,138, with the lowest PCRX earnings forecast at $83,574,861, and the highest PCRX earnings forecast at $90,764,096. On average, 4 Wall Street analysts forecast PCRX's earnings for 2026 to be $100,424,631, with the lowest PCRX earnings forecast at $92,112,078, and the highest PCRX earnings forecast at $114,578,439.

In 2027, PCRX is forecast to generate $114,129,111 in earnings, with the lowest earnings forecast at $112,781,130 and the highest earnings forecast at $115,477,093.

What is PCRX's revenue growth forecast for 2025-2027?

(NASDAQ: PCRX) Pacira Biosciences's forecast annual revenue growth rate of 7.43% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.66%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.9%.

Pacira Biosciences's revenue in 2025 is $705,848,000.On average, 4 Wall Street analysts forecast PCRX's revenue for 2025 to be $33,033,053,699, with the lowest PCRX revenue forecast at $32,967,586,725, and the highest PCRX revenue forecast at $33,178,321,186. On average, 4 Wall Street analysts forecast PCRX's revenue for 2026 to be $36,346,527,344, with the lowest PCRX revenue forecast at $35,927,754,384, and the highest PCRX revenue forecast at $36,947,277,824.

In 2027, PCRX is forecast to generate $39,229,994,849 in revenue, with the lowest revenue forecast at $37,963,655,973 and the highest revenue forecast at $41,230,264,790.

What is PCRX's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: PCRX) forecast ROA is N/A, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 14.08%.

What is PCRX's Price Target?

According to 1 Wall Street analyst that have issued a 1 year PCRX price target, the average PCRX price target is $30.00, with the highest PCRX stock price forecast at $30.00 and the lowest PCRX stock price forecast at $30.00.

The Wall Street analyst predicted that Pacira Biosciences's share price could reach $30.00 by May 9, 2026. The average Pacira Biosciences stock price prediction forecasts a potential upside of 31.75% from the current PCRX share price of $22.77.

What is PCRX's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: PCRX) Pacira Biosciences's current Earnings Per Share (EPS) is -$2.77. On average, analysts forecast that PCRX's EPS will be $1.95 for 2025, with the lowest EPS forecast at $1.86, and the highest EPS forecast at $2.02. On average, analysts forecast that PCRX's EPS will be $2.24 for 2026, with the lowest EPS forecast at $2.05, and the highest EPS forecast at $2.55. In 2027, PCRX's EPS is forecast to hit $2.54 (min: $2.51, max: $2.57).

What is PCRX's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: PCRX) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.